Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2026-06-28 @ 2:50 AM
Study NCT ID:
NCT05304169
Status:
COMPLETED
Last Update Posted:
2022-03-31
First Post:
2022-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
Sponsor:
Zodiac Produtos Farmaceuticos S.A.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Prostate Cancer | View |
Keywords: